Role of non-coding sequence variants in cancer

  title={Role of non-coding sequence variants in cancer},
  author={Ekta Khurana and Yao Fu and Dimple Chakravarty and Francesca Demichelis and Mark A. Rubin and Mark B. Gerstein},
  journal={Nature Reviews Genetics},
Patients with cancer carry somatic sequence variants in their tumour in addition to the germline variants in their inherited genome. Although variants in protein-coding regions have received the most attention, numerous studies have noted the importance of non-coding variants in cancer. Moreover, the overwhelming majority of variants, both somatic and germline, occur in non-coding portions of the genome. We review the current understanding of non-coding variants in cancer, including the great… 

Non-coding genetic variation in cancer.

Identification of Single Nucleotide Non-coding Driver Mutations in Cancer

An overview of in silico approaches used to prioritize somatic non-coding variants and the experimental methods used for functional validation and characterization of variants prioritized based on mutational burden and location within regulatory elements are presented.

Mapping and making sense of non-coding mutations in the genome.

This review discusses recent progress in identifying non-coding mutations and the analytical and experimental approaches utilized to interpret their functional roles and highlights the potential mechanisms by which a non-Coding mutation may exert its effect.

Non-Coding Variants in Cancer: Mechanistic Insights and Clinical Potential for Personalized Medicine

This review focuses on functional variants that reside in transcribed or not transcribed non-coding regions of the cancer genome and presents a collection of appropriate state-of-the-art methodologies to study them.

A catalog of cis-regulatory mutations in 12 major cancer types

It is shown that 301 non-coding somatic mutations identified have hallmark features of noncoding drivers; namely, that they confer a positive selection on growth, functionally disrupt transcription factor binding sites, and contribute to disease progression reflected in decreased overall patient survival.

Interpretation of the role of germline and somatic non-coding mutations in cancer: expression and chromatin conformation informed analysis

A better understanding of how to apply different regulatory data types into the study of non-coding mutations will enhance the discovery of novel mechanisms driving cancer.

Significance of Single-Nucleotide Variants in Long Intergenic Non-protein Coding RNAs

The significant role of SNVs within human lincRNA regions is summarized to help clarify the role of regulatory signatures involved in the modulation of lincRNAs in a tissue- or disorder-specific manner.

Transcription Factor-Centric Approach to Identify Non-Recurring Putative Regulatory Drivers in Cancer

The results show that focusing on the functional effects of non-coding mutations, rather than their recurrence, has the potential to identify putative regulatory drivers and the genes they dysregulate in tumor cells.

Functional germline variants as potential co-oncogenes

It is proposed that germline polymorphisms can function as oncogenic modifiers, or co-oncogenes, and these determine what complementary subsequent somatic events are required for full malignant transformation.



Genome-wide analysis of non-coding regulatory mutations in cancer

New frequency- and sequence-based approaches are used to comprehensively scan the genome for noncoding mutations with potential regulatory impact and identify recurrent mutations in regulatory elements upstream of PLEKHS1, WDR74 and SDHD, as well as previously identified mutations in the TERT promoter.

Systematic analysis of noncoding somatic mutations and gene expression alterations across 14 tumor types

This analysis provides a detailed pan-cancer view of TERT transcriptional activation but finds no clear evidence for frequent oncogenic promoter mutations beyond TERT.

Integrative Annotation of Variants from 1092 Humans: Application to Cancer Genomics

The approach can be readily used to prioritize variants in cancer and is immediately applicable in a precision-medicine context and can be further improved by incorporation of larger-scale population sequencing, better annotations, and expression data from large cohorts.

Targeted resequencing of the microRNAome and 3′UTRome reveals functional germline DNA variants with altered prevalence in epithelial ovarian cancer

This work identifies a potential new ovarian cancer locus and confirms that cancer resequencing efforts should not ignore the study of noncoding regions of cancer patients, and identifies a novel variant in the PCM1 3’UTR that is significantly associated with ovarian cancer.

Exploring functional variant discovery in non-coding regions with SInBaD

A new model SInBaD (Sequence-Information-Based-Decision-model) which relies on nucleotide conservation information to evaluate any annotated human variant in all known exons, introns, splice junctions and promoter regions, which demonstrates high prediction accuracy and demonstrates that variants predicted as functional have a significantly higher occurrence in cancer patients.

TERT Promoter Mutations in Familial and Sporadic Melanoma

A melanoma-prone family through linkage analysis and high-throughput sequencing was investigated and a disease-segregating germline mutation in the promoter of the telomerase reverse transcriptase (TERT) gene, which encodes the catalytic subunit of telomersase, caused up to twofold increase in transcription.

Recurrent Somatic Mutations in Regulatory Regions of Human Cancer Genomes

Using a new method that adjusts for sample- and genomic locus–specific mutation rates, this data demonstrates that many regulatory regions contain mutations under selective pressure and suggest a greater role for regulatory mutations in cancer than previously appreciated.

Signatures of accelerated somatic evolution in gene promoters in multiple cancer types

A novel signature of accelerated somatic evolution (SASE) marked by a significant excess of somatic mutations localized in a genomic locus is identified, and this work detects a hitherto under-appreciated and clinically important class of regulatory changes in cancer genomes.

OncoCis: annotation of cis-regulatory mutations in cancer

OncoCis is presented, a new method that enables identification of potential cis-regulatory mutations using cell type-specific genome and epigenome-wide datasets along with matching gene expression data, and it is demonstrated that the use of celltype-specific information and gene expression can significantly reduce the number of candidate cis-Regulatory mutations.

Cell-of-origin chromatin organization shapes the mutational landscape of cancer

It is shown that chromatin accessibility and modification, together with replication timing, explain up to 86% of the variance in mutation rates along cancer genomes, and that the cell type of origin of a cancer can be accurately determined based on the distribution of mutations along its genome.